Jove
Visualize
Contact Us

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anorectal Disorders: Do not throw the baby out with the dirty water.

Gastroenterology·2026
Same author

Future perspectives in esophageal manometry.

World journal of gastrointestinal surgery·2026
Same author

Evaluation of a Modified London Protocol to Diagnose Defecation Disorders With High-Definition Anorectal Manometry.

Neurogastroenterology and motility·2025
Same author

The Combination of Fluocinolone Acetonide and Ketocaine Hydrochloride in the Conservative Management of Symptomatic Hemorrhoidal Disease: An Overview of Preclinical and Clinical Data.

Journal of gastrointestinal and liver diseases : JGLD·2025
Same author

Rome Constipation Symptoms Augmented by Painful Defecation Predicts Specific Subtypes of Refractory Constipation.

Neurogastroenterology and motility·2025
Same author

Biofeedback efficacy for outlet dysfunction constipation: Clinical outcomes and predictors of response by a limited approach.

Neurogastroenterology and motility·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 18, 2026

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety
10:51

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety

Published on: January 20, 2012

Biofeedback therapy for dyssynergic defecation.

Giuseppe Chiarioni1, Steve Heymen, William-E Whitehead

  • 1Divisione di Riabilitazione Gastroenterologica dell, Universitade Verona, Azienda Ospedaliera di Verona, Centro Ospedaliero Clinicizzato, 37067 Valeggio sul Mincio (VR), Italy. chiarioni@tin.it

World Journal of Gastroenterology
|November 30, 2006
PubMed
Summary

Biofeedback training is a recommended treatment for dyssynergic defecation, a condition causing constipation due to pelvic floor muscle dysfunction. This therapy effectively teaches patients to relax these muscles during defecation, improving outcomes in adults.

Related Experiment Videos

Last Updated: Jul 18, 2026

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety
10:51

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety

Published on: January 20, 2012

Area of Science:

  • Gastroenterology
  • Pelvic Floor Physical Therapy
  • Behavioral Medicine

Background:

  • Dyssynergic defecation, characterized by paradoxical pelvic floor muscle contraction during attempted defecation, is a common cause of functional constipation.
  • It is considered a behavioral disorder as it lacks underlying morphological or neurological abnormalities.
  • Biofeedback training utilizes anal pressure or electromyographic measurements to guide patients in coordinating pelvic floor muscle relaxation during straining.

Discussion:

  • Randomized controlled trials in adults demonstrate biofeedback's superior efficacy over laxatives, sham biofeedback, and skeletal muscle relaxants for dyssynergic defecation.
  • The effectiveness of biofeedback is specific to patients with dyssynergic defecation, differentiating it from slow-transit constipation.
  • Evidence supporting biofeedback's superiority over laxatives in pediatric populations with dyssynergic defecation remains inconclusive.

Key Insights:

  • Biofeedback training is a highly effective treatment for adult dyssynergic defecation.
  • The therapy involves teaching patients to relax pelvic floor muscles and improve defecation techniques.
  • Treatment efficacy is specific to the diagnosis of dyssynergic defecation.

Outlook:

  • Further research is needed to establish the efficacy of biofeedback in pediatric populations.
  • Biofeedback represents a preferred, evidence-based treatment for adult dyssynergic defecation.
  • Investigating long-term outcomes and cost-effectiveness of biofeedback therapy is warranted.